Tumor-produced PGE2 (via COX-1/2) and IL-6 can likewise inhibit DCs differentiation through STAT3 signaling, skewing DCs to produce more IL-10 but less IL-12, thereby promoting regulatory or TH2 responses over TH1 cytotoxic immunity (11, 12). Here, IL10 is linked to neoplasm.